Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Ultragenyx Pharmaceutical (RARE) Leases (2019 - 2023)

Ultragenyx Pharmaceutical (RARE) has disclosed Leases for 5 consecutive years, with $26.4 million as the latest value for Q3 2023.

  • On a quarterly basis, Leases fell 8.08% to $26.4 million in Q3 2023 year-over-year; TTM through Sep 2023 was $26.4 million, a 8.08% decrease, with the full-year FY2022 number at $26.0 million, down 25.69% from a year prior.
  • Leases was $26.4 million for Q3 2023 at Ultragenyx Pharmaceutical, up from $19.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $40.5 million in Q4 2020 to a low of $19.2 million in Q2 2023.
  • A 5-year average of $31.6 million and a median of $32.2 million in 2019 define the central range for Leases.
  • Peak YoY movement for Leases: surged 55.61% in 2020, then tumbled 38.48% in 2023.
  • Ultragenyx Pharmaceutical's Leases stood at $30.3 million in 2019, then surged by 33.62% to $40.5 million in 2020, then dropped by 13.79% to $34.9 million in 2021, then decreased by 25.69% to $26.0 million in 2022, then grew by 1.8% to $26.4 million in 2023.
  • Per Business Quant, the three most recent readings for RARE's Leases are $26.4 million (Q3 2023), $19.2 million (Q2 2023), and $22.9 million (Q1 2023).